Printer Friendly

SCHERING-PLOUGH LICENSES FROM SCICLONE POTENTIAL HEPATITIS TREATMENT IN JAPAN

 MADISON, N.J., Jan. 27 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) and SciClone Pharmaceuticals, Inc.(NASDAQ-NMS: SCLN), of San Mateo, Calif., today announced a licensing agreement under which SciClone Pharmaceuticals International, Ltd. will give Schering-Plough K.K. (Japan) development and marketing rights in Japan to thymosin alpha 1, a synthetically produced thymic peptide that may be effective in treating chronic active hepatitis B and C.
 Under the agreement, Schering-Plough K.K. will undertake development, registration and marketing of thymosin alpha 1 in Japan in return for paying SciClone initial and milestone payments and buying bulk drug substance from SciClone. Development costs will be borne by Schering-Plough K.K. and a Japanese partner, yet to be named, that also will share marketing rights. Contingent upon successful research and development results, payments to SciClone and development costs could reach $35 million.
 Chronic viral hepatitis is a serious and well-recognized medical problem in Japan, which has an estimated 3 million hepatitis B and C carriers. Currently approved to treat the disease in Japan are various interferons, including Schering-Plough's Intron A' alpha interferon. In addition to Japan, Intron A' is approved for treating chronic active hepatitis B and C in the United States and more than 30 other countries.
 In Japan, there remains a pressing need for a more effective hepatitis B treatment, as interferons generally provide limited efficacy in Japanese patients for reasons that remain clinically unclear.
 With Intron A', Schering-Plough K.K. has established a strong presence among Japanese physicians treating chronic hepatitis C patients, as the product has proven quite effective in clearing evidence of the virus in a substantial percentage of those treated.
 "We are quite excited by the prospect of working with SciClone Pharmaceuticals in the development and commercialization of thymosin alpha 1 in Japan," said Dr. Anthony Wild, president, Schering-Plough K.K. "Given our strong presence in the hepatitis area with Intron A' and our broad development experience, we feel thymosin alpha 1 will complement Intron A' in the ever-challenging hepatitis market."
 "We are extremely pleased to be working with Schering-Plough, a company renowned as a pioneer in immunology and biotechnology research," said Thomas E. Moore, chairman and chief executive officer, SciClone Pharmaceuticals. "As we move forward toward gaining regulatory approval for thymosin alpha 1 in Japan, Schering-Plough K.K.'s extensive experience in the Japanese market and the approval process for hepatitis B and C in particular will be invaluable to SciClone."
 Thymosin alpha 1 is believed to act as a modulator of the body's immune system. SciClone has rights to the compound in Japan and other licensed territories. The compound was first discovered at the University of Texas.
 SciClone is primarily engaged in acquisition, development and marketing of pharmaceuticals on a worldwide basis. The company's primary focus is on therapeutics for infectious diseases (such as hepatitis B), cancers and immune system disorders that are chronic or life threatening, and place a major burden on the world's health care systems.
 Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
 -0- 1/27/93
 /CONTACT: Steve Galpin, Jr. of Schering-Plough, 201-822-7415/
 (SGP SCLN)


CO: Schering-Plough Corporation; SciClone Pharmaceuticals, Inc. ST: New Jersey, California IN: MTC SU: LIC

SH -- NY054 -- 9581 01/27/93 11:15 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1993
Words:548
Previous Article:BAKER HUGHES ANNOUNCES 1ST QUARTER EARNINGS
Next Article:UNITED STATES SURGICAL CORPORATION ANNOUNCES QUARTERLY DIVIDEND
Topics:


Related Articles
SCICLONE PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT/COMMERCIALIZATION AGREEMENT WITH SCHERING-PLOUGH K.K.
SCHERING-PLOUGH AND ICN PHARMACEUTICALS IN AGREEMENT TO DEVELOP COMBINATION USE 0F ALPHA INTERFERON, RIBAVIRIN FOR HEPATITIS C
SCHERING-PLOUGH AND ICN PHARMACEUTICALS IN AGREEMENT TO DEVELOP COMBINATION USE OF ALPHA INTERFERON, RIBAVIRIN FOR HEPATITIS C
ICN Sells its European Rights for Ribavirin For Hepatitis C Therapy to Schering-Plough for Increased Worldwide Royalties and $16.5 Million
Corvas to Receive $2.5 Million From Schering-Plough; Under Terms of Amended Hepatitis C Agreement.
SciClone's ZADAXIN(R) Commercially Available in Italy.
Enzon Announces Schering-Plough's PEGINTRON(TM) Approved for Treatment Of Hepatitis C in European Union (EU).
Schering-Plough and ICN Pharmaceuticals Announce Strategic Licensing Agreement.
FDA ASSIGNS PRIORITY REVIEW STATUS TO PEG-INTRON/REBETOL.
Schering-Plough licenses worldwide rights to pradefovir, oral hepatitis B treatment in development with Valeant and Metabasis.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters